Riesgo de enfermedad neumocócica en pacientes ancianos con y sin vacunación previa / Risk of pneumococcal disease in elderly patients with and without previous vaccination

Objetivos: Conocer la cobertura vacunal antineumocócica en pacientes ≥ 65 años, así como el riesgo de enfermedad neumocócica según hayan o no recibido dicha vacunación. Diseño: Estudio transversal, seguido de cohorte histórica. Emplazamiento: Ámbito urbano. Participantes: Se seleccionaron por muestreo sistemático 2.805 personas ≥ 65 años de la ciudad de Albacete. Mediciones principales: Variable dependiente: diagnóstico de enfermedad neumocócica y fecha. Variables independientes: edad, sexo, enfermedades crónicas, medicación, vacunación antineumocócica y fecha. Se revisaron las historias clínicas informatizadas, de 1-1-2009 a octubre-diciembre de 2015. Se ha realizado un análisis descriptivo, se ha calculado el riesgo relativo de aparición de enfermedad neumocócica según la vacunación y se ha realizado un análisis de supervivencia con el programa estadístico SPSS 17.0. Resultados: La mediana de edad era de 71 años; el 57,2% eran mujeres. Recibieron vacuna polisacárida el 46,0% (IC 95% 44,1-47,8). Solo 10 recibieron la conjugada. Fueron diagnosticadas de enfermedad neumocócica invasiva 22 personas, y de no invasiva, 153. El riesgo relativo de enfermedad neumocócica en vacunados frente a no vacunados, respectivamente para invasiva y no invasiva, era 1,59 (IC 95% 0,69-3,68) y 1,84 (IC 95% 1,33-2,54). Por regresión de Cox se demostró un mayor riesgo de enfermedad no invasiva para EPOC (1,95; IC 95% 1,32-2,89), tabaquismo (1,87; IC 95% 1,28-2,73), corticoterapia (1,73; IC 95% 1,08-2,79), vacunación polisacárida (141,41; IC 95% 5,92-3.378,49) y edad (1,11; IC 95% 1,08-1,14), con interacción entre estas 2 (0,94; IC 95% 0,91-0,98). Conclusiones: Existe un mayor riesgo de presentar enfermedad neumocócica en pacientes ≥ 65 años vacunados con la polisacárida, si bien habría que considerar un efecto protector en los vacunados de mayor edad

Objectives: To know the pneumococcal vaccination coverage in patients ≥ 65 years old, as well as the risk of pneumococcal disease according to whether or not they received such vaccination. Design: Cross-sectional study, followed by historical cohort. Location: Urban area. Participants: By systematic sampling, 2,805 people ≥ 65 years from the city of Albacete were selected. Main measurements: Dependent variable: diagnosis of pneumococcal disease and date. Independent variables: age, sex, chronic pathologies, medication, pneumococcal vaccination and date. The computerized medical records were reviewed, from 1-1-2009 to October-December 2015. A descriptive analysis was carried out, the relative risk of the onset of pneumococcal disease according to vaccination has been calculated, and survival analysis has been carried out, with the statistical program SPSS 17.0. Results: Median age 71 years; 57.2% were women; 46% received polysaccharide vaccine (95% CI 44.1-47.8). Only 10 people received conjugated vaccine. Twenty-two people were diagnosed with invasive pneumococcal disease and 153 non-invasive. The relative risk of pneumococcal disease in vaccinated versus unvaccinated, respectively for invasive and non-invasive, was 1.59 (95% CI 0.69-3.68) and 1.84 (95% CI 1.33-2.54). Cox regression showed a higher risk of non-invasive disease for COPD (1.95; 95% CI 1.32-2.89), smoking (1.87; 95% CI 1.28-2.73), corticoid-therapy (1.73; 95% CI 1.08-2.79), polysaccharide vaccination (141.41; 95% CI 5.92-3,378.49) and age (1.11; 95% CI 1.08-1.14), with interaction between these 2 (0.94, 95% CI 0.91-0.98). Conclusions: There is an increased risk of pneumococcal disease in patients ≥ 65 years vaccinated with polysaccharide, although with a protective effect in vaccinated older

Seguimiento a dos años de pacientes con diabetes mellitus tipo 2 atendidos en dos centros de salud, en España y Portugal / Two-year follow-up of type 2 diabetic patients seen in two health care centers in Spain and Portugal

Objetivo: Conocer los cambios en el grado de control después de 2 años, de pacientes con diabetes mellitus tipo 2 (DM2) en un centro de Salud español (público, SESCAM) y otro portugués (Unidad de Salud Funcional). Diseño: Estudio de cohorte. Emplazamiento: Atención Primaria. Participantes: Pacientes con DM2 que revisados 2 años después de un primer control (julio y noviembre del 2014, respectivamente en Portugal y España). Mediciones Principales: A partir de las historias clínicas informatizas se obtuvieron los siguientes datos: sexo, edad, años de evolución, índice de masa corporal (IMC), microalbuminuria, hemoglobina glicosilada (HbA1c), perfil lipídico, presencia de complicaciones y tratamiento. La información fue introducida en una base de datos informatizada por medio del programa estadístico SPSS 17.0. Se realizó estadística descriptiva y comparación de proporciones y medias/medianas. Resultados: En 2014 se estudiaron 200 pacientes portugueses y 278 españoles. Dos años después, se disponía de información en sus historias clínicas para 135 portugueses y 248 españoles. La media de edad de estos pacientes en 2016 era de 71,2 años (DE: 11,0), con 46,0 % de mujeres. No había diferencias en la distribución por edad y sexo entre ambos centros. La mediana de variación en la HbA1c a los 2 años era 0,0 (rango intercuartil:-0,4 a 0,5), sin diferencias estadísticamente significativas en los portugueses y un moderado aumento (p=0,05) para los españoles. Los portugueses presentaban una disminución media del IMC de 0,05 (IC95 %:-0,27 a 0,37) y los españoles tenían un aumento medio de 0,07 (IC95 %:-0,27 a 0,41), sin existir diferencias estadísticamente significativas. Conclusiones: A los 2 años de seguimiento, los pacientes portugueses mostraron una leve reducción de peso, con estabilidad en sus cifras de HbA1c, mientras que los españoles empeoraron ligeramente en ambos parámetros

Objective: The aim of the study is to know the changes in the degree of control of patients with type 2 diabetes mellitus in a Spanish health center (public, SESCAM) and a Portuguese health center (Functional Health Unit) after a two-year follow-up period. Design: Cohort study. Location: Primary Care. Participants: Patients with type 2 diabetes who were reviewed two years after a first control (July and November 2014, respectively in Portugal and Spain). Main measurements: The data obtained from the computerized clinical records were sex, age, years of disease course, body mass index (BMI), microalbuminuria, glycosylated hemoglobin (HbA1c), lipid profile, complications, and treatment. The information was entered into a computerized database with the statistical program SPSS 17.0. Descriptive statistics and comparison of proportions and means/medians were performed. Results: 200 Portuguese patients and 278 Spanish patients were studied in 2014. Information on their clinical follow-up was available two years after for 135 Portuguese and 248 Spanish. The mean age of these patients in 2016 was 71.2 years (SD: 11.0), with 46.0% of women. There were no differences in the distribution by age and sex in both centers. The median of variation in HbA1c after 2 years was 0.0 (interquartile range:-0.4 to 0.5), without statistically significant (NS) differences for Portuguese patients and moderate increase (p=0.05) for Spanish patients. The Portuguese presented a mean BMI decrease of 0.05 (95%CI:-0.27 to 0.37) and Spanish patients had a mean increase of 0.07 (95%CI:-0.27 to 0.41), NS differences. Conclusion: After 2 years of follow-up, Portuguese patients showed a slight weight reduction, with stability in their HbA1c levels, while Spanish patients worsened slightly in both parameters

[Risk of pneumococcal disease in elderly patients with and without previous vaccination]. / Riesgo de enfermedad neumocócica en pacientes ancianos con y sin vacunación previa.

OBJECTIVES: To know the pneumococcal vaccination coverage in patients≥65 years old, as well as the risk of pneumococcal disease according to whether or not they received such vaccination. DESIGN: Cross-sectional study, followed by historical cohort. LOCATION: Urban area. PARTICIPANTS: By systematic sampling, 2,805 people≥65 years from the city of Albacete were selected. MAIN MEASUREMENTS: Dependent variable: diagnosis of pneumococcal disease and date. INDEPENDENT VARIABLES: age, sex, chronic pathologies, medication, pneumococcal vaccination and date. The computerized medical records were reviewed, from 1-1-2009 to October-December 2015. A descriptive analysis was carried out, the relative risk of the onset of pneumococcal disease according to vaccination has been calculated, and survival analysis has been carried out, with the statistical program SPSS 17.0. RESULTS: Median age 71 years; 57.2% were women; 46% received polysaccharide vaccine (95% CI 44.1-47.8). Only 10 people received conjugated vaccine. Twenty-two people were diagnosed with invasive pneumococcal disease and 153 non-invasive. The relative risk of pneumococcal disease in vaccinated versus unvaccinated, respectively for invasive and non-invasive, was 1.59 (95% CI 0.69-3.68) and 1.84 (95% CI 1.33-2.54). Cox regression showed a higher risk of non-invasive disease for COPD (1.95; 95% CI 1.32-2.89), smoking (1.87; 95% CI 1.28-2.73), corticoid-therapy (1.73; 95% CI 1.08-2.79), polysaccharide vaccination (141.41; 95% CI 5.92-3,378.49) and age (1.11; 95% CI 1.08-1.14), with interaction between these 2 (0.94, 95% CI 0.91-0.98). CONCLUSIONS: There is an increased risk of pneumococcal disease in patients≥65 years vaccinated with polysaccharide, although with a protective effect in vaccinated older.